Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

LuxembourgBack to Luxembourg

Clinical trials in Libramont-Chevigny

14 clinical trials in Libramont-Chevigny, Luxembourg. Every trial is listed in the EU Clinical Trials Register and updated daily.

Libramont-Chevigny at a glance
14
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

14 trials in Libramont-Chevigny

Open in trial search

Prostate cancer

Recruiting

A study of saruparib with radiotherapy and hormone therapy for men with high-risk prostate cancer who have a BRCA gene mutation

Registered drug
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone Acetate
  • Sponsor:AstraZeneca AB

Embolism

Not yet recruiting

A study to evaluate the effectiveness of REGN7508 for preventing blood clots in adults with solid tumors undergoing cancer treatment.

Investigational
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:REGN7508
  • Sponsor:Regeneron Pharmaceuticals Inc.

Hormone-refractory prostate cancer+1

Not recruiting

Study of Lorigerlimab and Docetaxel for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Dexamethasone
  • Sponsor:Macrogenics Inc.

Hormone-refractory prostate cancer+1

Not recruiting

Study of Vobramitamab Duocarmazine and Prednisone for Patients with Metastatic Castration-Resistant Prostate Cancer

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Prednisone
  • Sponsor:Macrogenics Inc.

Endometrial cancer recurrent+4

Not recruiting

Study on the Safety and Effectiveness of IMGN151 for Women with Recurrent Endometrial and Ovarian Cancer

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Brimonidine Tartrate
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Breast cancer

Not recruiting

Study on the Effects and Safety of Camizestrant (AZD9833) Compared to Fulvestrant in Postmenopausal Women with Advanced ER-Positive HER2-Negative Breast Cancer

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Camizestrant
  • Sponsor:AstraZeneca AB

Neoplasm

Not recruiting

Study on DF1001, Nivolumab, and Paclitaxel for Patients with Advanced Solid Tumors

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:DF1001
  • Sponsor:Dragonfly Therapeutics Inc.

Ductal adenocarcinoma of pancreas

Not recruiting

Study of SBP-101, Nab-Paclitaxel, and Gemcitabine for Patients with Metastatic Pancreatic Cancer

Registered drug
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Gemcitabine
  • Sponsor:Panbela Therapeutics Inc.

Breast cancer stage IV

Not recruiting

Study of Eftilagimod Alpha and Paclitaxel in Patients with HER2-Negative/Low Metastatic Breast Cancer

Registered drug
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Eftilagimod Alfa
  • Sponsor:Immutep

Breast cancer+1

Not recruiting

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Novartis Pharma AG

Colorectal cancer metastatic

Not recruiting

Study on the Safety and Effectiveness of Magrolimab with Bevacizumab and Drug Combination for Patients with Advanced Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Gilead Sciences Inc.

Colon cancer stage III+1

Not recruiting

Study on Aspirin for Preventing Recurrence and Improving Survival in Patients with Resected Colon Cancer

Registered drug
Countries:LuxembourgLuxembourg
  • Participants:18–64 years · 65+ years
  • Substances:Acetylsalicylic Acid
  • Sponsor:Antwerp University Hospital

Other cities in Luxembourg

The busiest research cities in the country

All 2 cities in Luxembourg

Clinical research in Libramont-Chevigny

What the registry says about research in the country

01 Breast Cancer Research

Multiple clinical trials focusing on advanced breast cancer treatments, particularly for patients with different receptor statuses including HER2-negative and hormone receptor-positive cases. Studies evaluate novel therapeutic combinations and treatment approaches.

  • Hormone receptor-positive treatments
  • Triple-negative breast cancer therapies
  • Combination therapy approaches
02 Lung Cancer Studies

Innovative research exploring non-small cell lung cancer treatments and new therapeutic options for extensive-stage small cell lung cancer. Trials evaluate various treatment combinations and compare effectiveness with standard therapies.

  • Advanced NSCLC treatments
  • Immunotherapy combinations
  • Novel therapeutic approaches
03 Gynecological Oncology

Comprehensive studies investigating treatments for various gynecological cancers, including endometrial, ovarian, and fallopian tube cancers. Research focuses on combining immunotherapy with standard treatments.

  • Endometrial cancer therapies
  • Ovarian cancer treatments
  • Advanced peritoneal cancer approaches
04 Urological Cancer Research

Clinical trials examining new treatments for bladder cancer and prostate cancer, including studies of innovative therapeutic combinations and maintenance therapies.

  • Non-muscle invasive bladder cancer
  • Metastatic prostate cancer
  • Novel combination approaches
Back to LuxembourgAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.